2026-04-30
5 分钟The Economist.
Hi there, it's Jason Palmer here, co-host of The Intelligence, our daily news and current affairs podcast.
This is Editor's Picks.
You're about to hear an article from the latest edition of The Economist read aloud.
Enjoy.
Joe Rogan extolled the benefits of ibogaine, a psychedelic drug, for treating opioid addiction.
Sounds great, Donald Trump replied.
Do you want FDA approval?
Let's do it.
Within a week, on April 18th, Mr Trump signed an executive order
that sent the share prices of psychedelics makers soaring.
Among other things, it promised new funding for research into the field and instructed the Food and Drug Administration
or FDA to issue priority vouchers that will speed up the review of selected drugs.
It is a watershed moment for a field that has struggled for years.
From the 1940s to the 1960s, work on psychedelics as medicines flourished.
Tens of thousands of people used them as adjuncts to psychotherapy,
with promising signs in alcoholism, addiction, PTSD and mood disorders.
But the field floundered amid the moral panic over the 1960s counterculture and stricter rules on research
and use that made further study difficult.
Mr Trump's decision, then, is welcome news for the millions of people suffering with conditions